Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Lorbrena® is an anaplastic lymphoma kinase inhibitor indicated as a second or third-line treatment of advanced non-small cell lung cancer. Credit: US National Library of Medicine, National Institutes of Health, Health & Human Services.

  • Lorbrena
  • Lorbrena
  • Lorbrena

Go Top